Stemline Therapeutics Inc. (STML) Stock Rating Lowered by Zacks Investment Research
Stemline Therapeutics Inc. (NASDAQ:STML) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.
According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
Other equities research analysts have also recently issued reports about the stock. Jefferies Group reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, August 5th. Roth Capital restated a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a report on Thursday, August 25th. Finally, Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, November 8th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.50.
Stemline Therapeutics (NASDAQ:STML) opened at 12.60 on Friday. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $14.20. The firm has a 50 day moving average of $11.71 and a 200-day moving average of $8.52. The stock’s market cap is $224.60 million.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oak Ridge Investments LLC boosted its position in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares during the period. Emerald Acquisition Ltd. purchased a new position in Stemline Therapeutics during the second quarter valued at approximately $129,000. State Treasurer State of Michigan purchased a new position in Stemline Therapeutics during the third quarter valued at approximately $217,000. Paradigm Asset Management Co. LLC purchased a new position in Stemline Therapeutics during the second quarter valued at approximately $141,000. Finally, Nationwide Fund Advisors boosted its position in Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 8,670 shares during the period. Hedge funds and other institutional investors own 53.21% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.